{"id":"W3131900383","doi":"10.1158/1538-7445.sabcs20-gs1-02","title":"Abstract GS1-02: Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Palbociclib; Medicine; Oncology; Breast cancer; Internal medicine; Clinical endpoint; Neoadjuvant therapy; Taxane; Chemotherapy; Cancer; Metastatic breast cancer; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001185051,0.002134252,0.002129027,0.0006485657,0.0003338279,0.001250602,0.001375286,0.001396159,0.0147407],"category_scores_gemma":[0.0006900198,0.0007177209,0.001237679,0.0006425544,0.001158111,0.0008286656,0.0003383333,0.003185448,0.00210729],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001187535,"about_ca_system_score_gemma":0.002130106,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001713123,"about_ca_topic_score_gemma":0.00483958,"domain_scores_codex":[0.9996778,0.0001541908,0.0000130599,0.00005783412,0.00003122331,0.00006589468],"domain_scores_gemma":[0.9995646,0.00005601286,0.00007074102,0.0000302973,0.00002739005,0.0002509528],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8756486,0.04090561,0.002219259,0.001269022,0.001442453,0.0001174945,0.0000906996,0.001260557,0.02088664,0.0002830696,0.005988079,0.04988842],"study_design_scores_gemma":[0.8852717,0.1089504,0.002949497,0.00002943452,0.0002694888,0.00006340552,0.00002058729,0.0003096057,0.0009179599,0.0001035335,0.001099376,0.00001505259],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9736669,0.004712516,0.0005471073,0.001165757,0.0003493621,0.006136212,0.005859596,0.0004265777,0.007135836],"genre_scores_gemma":[0.9716253,0.003503874,0.001380611,0.002453152,0.0003296022,0.003854219,0.00712033,0.00006667891,0.009666034],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0147407,"threshold_uncertainty_score":0.04931259,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01504576283886612,"score_gpt":0.3162328166623994,"score_spread":0.3011870538235333,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}